NRIX vs RVMD
NRIX: Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi. RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
Side-by-side fundamentals
| Metric | NRIX | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $25.22 | $197.81 | |
| Market cap as of 2026-08-08 | $2.6B | $42.4B | |
| PEG as of 2026-08-08 | -0.23 | -0.23 | RVMD lower |
| Net margin as of 2026-08-08 | -928.4% | -2833.9% | NRIX higher |
| Operating margin as of 2026-08-08 | -982.4% | -3145.0% | NRIX higher |
| ROE as of 2026-08-08 | -76.1% | -54.1% | RVMD higher |
| ROA as of 2026-08-08 | -57.3% | -39.1% | RVMD higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.19 | NRIX lower |
| Revenue growth (YoY) as of 2026-08-08 | -58.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +29.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-08 | 1.79 | 1.40 | |
| 1-year return as of 2026-08-06 close | +141.1% | +439.4% | RVMD higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.